Literature DB >> 28798979

Mucosa-associated invariant T cells infiltrate hepatic metastases in patients with colorectal carcinoma but are rendered dysfunctional within and adjacent to tumor microenvironment.

Christopher R Shaler1, Mauro E Tun-Abraham2, Anton I Skaro2, Khashayarsha Khazaie3, Alexandra J Corbett4, Tina Mele2,5, Roberto Hernandez-Alejandro2,6, S M Mansour Haeryfar7,8,9,10.   

Abstract

Mucosa-associated invariant T (MAIT) cells are innate-like T lymphocytes that are unusually abundant in the human liver, a common site of colorectal carcinoma (CRC) metastasis. However, whether they contribute to immune surveillance against colorectal liver metastasis (CRLM) is essentially unexplored. In addition, whether MAIT cell functions can be impacted by chemotherapy is unclear. These are important questions given MAIT cells' potent immunomodulatory and inflammatory properties. Herein, we examined the frequencies and functions of peripheral blood, healthy liver tissue, tumor-margin and tumor-infiltrating MAIT cells in 21 CRLM patients who received no chemotherapy, FOLFOX, or a combination of FOLFOX and Avastin before they underwent liver resection. We found that MAIT cells, defined as CD3ε+Vα7.2+CD161++ or CD3ε+MR1 tetramer+ cells, were present within both healthy and tumor-afflicted hepatic tissues. Paired and grouped analyses of samples revealed the physical proximity of MAIT cells to metastatic lesions to drastically influence their functional competence. Accordingly, unlike those residing in the healthy liver compartment, tumor-infiltrating MAIT cells failed to produce IFN-γ in response to a panel of TCR and cytokine receptor ligands, and tumor-margin MAIT cells were only partially active. Furthermore, chemotherapy did not account for intratumoral MAIT cell insufficiencies. Our findings demonstrate for the first time that CRLM-penetrating MAIT cells exhibit wide-ranging functional impairments, which are dictated by their physical location but not by preoperative chemotherapy. Therefore, we propose that MAIT cells may provide an attractive therapeutic target in CRC and that their ligands may be combined with chemotherapeutic agents to treat CRLM.

Entities:  

Keywords:  Chemotherapy; Colon cancer; Immune surveillance; Liver metastasis; MAIT cells; Tumor-infiltrating lymphocytes

Mesh:

Year:  2017        PMID: 28798979     DOI: 10.1007/s00262-017-2050-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

Review 1.  Mucosal-Associated Invariant T Cells in Chronic Inflammatory Liver Disease.

Authors:  Fabian J Bolte; Barbara Rehermann
Journal:  Semin Liver Dis       Date:  2018-02-22       Impact factor: 6.115

Review 2.  Mucosal-associated invariant T cells and disease.

Authors:  Amine Toubal; Isabelle Nel; Sophie Lotersztajn; Agnès Lehuen
Journal:  Nat Rev Immunol       Date:  2019-10       Impact factor: 53.106

Review 3.  Mucosal-Associated Invariant T Cells: New Insights into Antigen Recognition and Activation.

Authors:  Xingxing Xiao; Jianping Cai
Journal:  Front Immunol       Date:  2017-11-10       Impact factor: 7.561

Review 4.  Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies.

Authors:  Katie Healy; Anna Pasetto; Michał J Sobkowiak; Chai Fen Soon; Markus Cornberg; Soo Aleman; Margaret Sällberg Chen
Journal:  Cells       Date:  2020-06-16       Impact factor: 6.600

Review 5.  The Role of CD1d and MR1 Restricted T Cells in the Liver.

Authors:  Wenyong Huang; Wenjing He; Xiaomin Shi; Xiaoshun He; Lang Dou; Yifang Gao
Journal:  Front Immunol       Date:  2018-10-30       Impact factor: 7.561

6.  Tumor-infiltrating mucosal-associated invariant T (MAIT) cells retain expression of cytotoxic effector molecules.

Authors:  Patrik Sundström; Louis Szeponik; Filip Ahlmanner; Malin Sundquist; Justin S B Wong; Elinor Bexe Lindskog; Bengt Gustafsson; Marianne Quiding-Järbrink
Journal:  Oncotarget       Date:  2019-04-19

Review 7.  Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer.

Authors:  Yongyan Chen; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2020-10-12       Impact factor: 11.530

Review 8.  Mouse models illuminate MAIT cell biology.

Authors:  Huimeng Wang; Zhenjun Chen; James McCluskey; Alexandra J Corbett
Journal:  Mol Immunol       Date:  2020-12-22       Impact factor: 4.407

Review 9.  Biased MAIT TCR Usage Poised for Limited Antigen Diversity?

Authors:  Michael N T Souter; Sidonia B G Eckle
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

Review 10.  Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.

Authors:  Dorian Stolk; Hans J van der Vliet; Tanja D de Gruijl; Yvette van Kooyk; Mark A Exley
Journal:  Front Immunol       Date:  2018-09-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.